Institute of Immunology, Medical Faculty, Technical University of Dresden, Dresden, Germany.
Cancer Lett. 2013 Jul 10;335(1):119-27. doi: 10.1016/j.canlet.2013.02.003. Epub 2013 Feb 9.
Imiquimod and resiquimod represent Toll-like receptor (TLR) 7 and 8 agonists, which emerged as attractive candidates for tumor therapy. To elucidate immune cells, which mainly contribute to TLR7/8-mediated antitumoral activity, we investigated the impact of imiquimod and resiquimod on native human 6-sulfo LacNAc (slan) dendritic cells (DCs). We found that both TLR7/8 agonists significantly improve the release of various proinflammatory cytokines by slanDCs and promote their tumor-directed cytotoxic activity. Furthermore, resiquimod efficiently augmented the ability of slanDCs to stimulate T cells and natural killer cells. These results indicate that imiquimod and resiquimod trigger various immunostimulatory properties of slanDCs, which may contribute to their antitumor effects.
咪喹莫特和瑞喹莫特是 Toll 样受体 (TLR) 7 和 8 的激动剂，它们作为肿瘤治疗的有吸引力的候选药物而出现。为了阐明主要有助于 TLR7/8 介导的抗肿瘤活性的免疫细胞，我们研究了咪喹莫特和瑞喹莫特对天然人 6-硫酸神经氨酸 (sLan) 树突状细胞 (DCs) 的影响。我们发现，两种 TLR7/8 激动剂都显著提高了 slanDCs 释放各种促炎细胞因子的能力，并促进了它们的肿瘤定向细胞毒性活性。此外，瑞喹莫特有效地增强了 slanDCs 刺激 T 细胞和自然杀伤细胞的能力。这些结果表明，咪喹莫特和瑞喹莫特触发了 slanDCs 的各种免疫刺激特性，这可能有助于它们的抗肿瘤作用。
